Healthcare
60 Degrees Pharmaceuticals, Inc.(SXTP)
Live Price
Offline$1.64
+1.23% today
1Y Change
-80.93%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- โ
- Revenue Growth
- +65.5%
- EPS Growth
- +84.2%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
60 Degrees Pharmaceuticals, Inc. (SXTP) is a Healthcare stock with listed on NASDAQ. The stock last traded around $1.64 and down 80.9% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +65.5%, EPS growth of +84.2%, a dividend yield of 0.0%. What stands out right now is revenue +65.5%, EPS +84.2%, free cash flow -21.2% with operating margin -771.6% and ROIC -219.7%. Valuation is more restrained than many high-expectation growth names at price/sales 1.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SXTP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+65.5% vs +7.6% peer median
Operating Margin
Below sector median
-771.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +65.5% and EPS at +84.2%, with operating margin around -771.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | -0.7% | +0.0% | โ |
2026 Mar 26, 2026 | +35.5% | +0.7% | +24.8% | +9.4% |
2025 Nov 13, 2025 | -43.5% | -22.2% | -13.7% | -27.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SXTP
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SXTP Max Drawdown
-86.97%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SXTP and SPY.
Company Overview
60 Degrees Pharmaceuticals, Inc.
NASDAQ Capital Market
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
- Leadership
- Geoffrey Stuart Dow
- IPO Date
- Jul 12, 2023
- Employees
- 3
- Street Address
- 1025 Connecticut Avenue NW
- Mailing
- Washington, DC, 20036
- Region
- Washington, DC, US
- Reporting Currency
- USD
- Investor Line
- 202 327 5422
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.0
- Price/Sales
- 1.3
- Price/Book
- 0.3
Growth
- Revenue
- +65.5%
- EPS
- +84.2%
- Free Cash Flow
- -21.2%
Profitability
- Gross Margin
- 22.3%
- Operating Margin
- -771.6%
- Net Margin
- -732.8%
- ROE
- -204.2%
- ROIC
- -219.7%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 2.66
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.